Quotient Bioresearch Highlights Enhanced Benefits of 14C Radiolabelled Studies via Expert Webinar Series
News Apr 02, 2010
Quotient Bioresearch announces a new educational webinar series entitled "14C Enabled Drug Development in Pharmaceutical R&D."
The webinars will consist of scientific presentations from industry experts focused on a broad range of drug development activities that can be enhanced by 14C radiolabelled studies.
The webinar series begins April 27 and runs during May and early June 2010.
Each of the four webinars will cover specific topics: Metabolism; Species and Interspecies Dependent Metabolism; ivPK and Absolute Bioavailability; and Quotient's new Synthesis-to-Clinic platform. All four webinars are free of charge to attend and will also be available to view on demand after the event.
Each webinar will run twice a day at the following times:
7am and 9am Pacific Time/ 10am and 12pm Eastern Time/ 3pm and 5pm UK
Webinar 1: Metabolism, Tuesday 27 April
Professor Tom Baillie, Dean of the School of Pharmacy at the University of Washington and formerly Global VP Drug Metabolism and Pharmacokinetics with Merck, will discuss how the FDA MIST and ICH M3(r2) guidelines encourage metabolism investigations earlier than ever in drug development.
The presentation will look at how industry is approaching this through study designs and use of new technologies such as AMS (Accelerator Mass Spectrometry) and Orbitrap to enhance the information that can be generated during metabolism studies. The webinar will explore future approaches to conducting metabolism studies.
Webinar 2: Inter and Intra-species Differences in Drug Metabolism, Tuesday 11 May
Professor Alan Rettie, Chairman, Department of Medicinal Chemistry, University of Washington, will explore the impact of inter-species differences on metabolism studies and the impact of inter-species genetic polymorphisms on metabolism. The presentation will also provide case studies to highlight notable cases of metabolism directing the individual response.
Webinar 3: ivPK & Absolute Bioavailability, Tuesday 25 May
Dr. Bob Ings, RMI Pharmacokinetics & ex VP DMPK Roche Palo Alto, will illustrate how the routine use of iv microtracer dosing can enhance drug development and discuss what the data offer in terms of understanding absolute bioavailability, clearance characteristics and drug performance.
Webinar 4: Synthesis-to-Clinic Platform, Tuesday 8 June
The final presentation will explain how the themes discussed in the first three webinars can be comprehensively addressed by the services available through Quotient's Synthesis-to-Clinic platform. Case histories will be used to showcase recent applications of the Synthesis-to-Clinic platform and there will also be a Q&A of key topics of interest raised throughout the webinar series.
The cholesterol-lowering drugs called statins have demonstrated substantial benefits in reducing the risk of heart attacks and strokes caused by blood clots (ischemic strokes) in at-risk patients. Since statins are associated with a low risk of side effects, the benefits of taking them outweigh the risks, according to a scientific statement from the American Heart Association that reviewed multiple studies evaluating the safety and potential side effects of these drugs.READ MORE
18th International Conference on Pharmaceutics & Novel Drug Delivery Systems
May 27 - May 28, 2019
World Congress on Recent Advances in Aquaculture Research & Fisheries
Jun 10 - Jun 11, 2019